Marina Caballero-Bellón

Dr. Marina Caballero-Bellón

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Biomarkers
Verified
Journal Article
Closed access
MCMarina Caballero-Bellón
Marina Caballero-Bellón
SBSara Bobillo-Perez
Sara Bobillo-Perez
CACatalà A
Català A
AAAlonso-Saladrigues A
Alonso-Saladrigues A
VAValls A
Valls A
JIJordan I
Jordan I
PurposeChimeric antigen receptor (CAR) T-cell CD19 therapy has changed the treatment paradigm for patients with relapsed/refractory B-cell acute lymphoblastic leukemia. It is frequently associated with potentially severe toxicities: cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and admission to PICU is often required. Some biomarkers seem to correlate with CRS severity. Our goal is to elucidate the role of procalcitonin (PCT), C-reactive protein (CRP) and ferritin in the context of CRS following CAR T-cell infusion to predict its severity and PICU admission.MethodsProspective observational study (2016-2022) in children and young adult who received CAR T-cell therapy (Tisagenlecleucel/ARI-0001). We collected epidemiologic data, specific CAR T-cell toxicities, PICU admission, biomarker results (procalcitonin, CRP and ferritin), length of stay and mortality. Biomarkers were analyzed considering two values: the highest value during ward admission, and the highest overall value including PICU admission.ResultsSeventy-seven patients were included. Median age at infusion was 9.1 years (IQR 6-13), 49.4% were females. Before CAR T-cell infusion, the median bone marrow blast was 9% (IQR 0-59). The most frequent toxicity was CRS in 62 patients (80.5%), it was severe in 18 cases (23.4%). Fourteen patients (18.1%) had ICANS. Thirty-one patients (40.3%) required admission to the PICU. PCT and ferritin were higher in patients admitted to PICU (PCT 0.8 ng/ml vs 0.15 ng/ml, p < 0.001, ferritin 5490 vs. 2900 ug/l, p < 0.019). The proposed cut-off for PCT to predict admission to PICU is 0.55 ng/mL, presenting a sensitivity of 67.7% and a specificity of 86.7%. The maximum value of the three biomarkers was higher in those who presented any primary outcome: development of a severe CRS, the need for admission to PICU, and in-hospital mortality. Biomarkers were higher in those who needed inotropic or respiratory support.ConclusionsPCT levels increase after CAR-T cell therapy in the setting of systemic inflammation and could be a predictor of PICU admission and evolution to death. Further research studying its role in the context of CRS and the differential diagnosis between infection and CRS is needed to better understand the biology of this biomarker and to define its value in clinical practice.

25 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DQDiannet Quintero-García
Diannet Quintero-García
ASAina Seguí
Aina Seguí
APAndrea G. Palau
Andrea G. Palau
APAlicia Pablos
Alicia Pablos
MNMariona Nadal
Mariona Nadal
Jaume MoraJaume Mora
Jaume Mora
Recent therapeutic advances have significantly transformed the management of selected pediatric malignancies. We conducted a narrative review of recently approved therapies with demonstrated clinical impact in pediatric oncology. Evidence from pivotal clinical trials was integrated with real-world experience at the Pediatric Cancer Center Barcelona (PCCB). Fifty-three new oncological drugs with pediatric indication were available in 2025 that were not in routine clinical practice in 2020. We reviewed 18, those available at the PCCB, to demonstrate their meaningful clinical activity, the improved disease control and favorable toxicity profiles. Overall, 688 patients have benefited from these new agents. Real-world experience supports their feasibility and clinical benefit in many pediatric cancers. We realized that a significant number of novel therapies have been approved in the last 5 years and represent an important step toward precision oncology in pediatric cancer. Their integration into clinical practice is reshaping treatment paradigms and offering real opportunities for patients with otherwise limited options. Ongoing studies will define their long-term impact, optimal sequencing, and role within multimodal treatment strategies.

30 October 2025 in Neuro-Oncology Pediatrics
Verified
Journal Article
Open access
MCMarina Caballero-Bellón
Marina Caballero-Bellón
MWMari Wilhelmsson
Mari Wilhelmsson
JWJonathan D Wasserman
Jonathan D Wasserman
TMTara McKeown
Tara McKeown
DTDerek S Tsang
Derek S Tsang
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy
Background: Treatment for medulloblastoma can lead to significant long-term endocrine sequelae, including growth hormone (GH) deficiency. There has been some concern that GH replacement can increase the risk of tumor relapse. Our goal was to assess the risk of recurrence after GH therapy in medulloblastoma (MB) patients treated with ­modern, molecularly informed protocols. Methods: We conducted a retrospective observational cohort study at a tertiary pediatric hospital from January 1999 to December 2022. Patients < 18 years old with MB who received craniospinal irradiation (CSI) were included, treated according to contemporary risk-adapted protocols. Epidemiological, molecular, and clinical data were collected. Results: A total of 148 patients with MB were treated with CSI, with a median age of 8.3 years (IQR 5.9-10.8). The molecular subgroups included Group 4 (n = 69, 46.6%), Group 3 (n = 27, 18.2%), WNT (n = 21, 14.2%), and SHH (n = 20, 13.5%). During follow-up, 79 patients (53.4%) were diagnosed with GH deficiency, and 73 of them initiated GH therapy. We found no association between sex (P = 1), presence of metastases (P = .14), or molecular subgroup (P = .71) and the use of GH therapy. Thirty-four patients (22.9%) relapsed during follow-up, with 10 of them receiving GH therapy (13.7% of all patients on GH). Progression-free survival (PFS) was higher among those who received GH replacement therapy, even within each subgroup independently. In a multivariate analysis of patients who had not relapsed at least 2 years post-diagnosis, GH replacement was associated with significantly improved overall survival (OS) and a trend toward improved PFS (PFS: HR 0.35, 95% CI, 0.12-1.08, P = .068; OS: HR 0.34, 95% CI, 0.12-0.99, P = .049). Conclusions: The use of GH is not associated with an increased risk of recurrence or death in children with medulloblastoma treated with CSI according to current protocols. Our results provide further reassurance that all children with requiring treatment for growth hormone deficiency after medulloblastoma therapy should be offered physiological growth hormone replacement.

29 June 2022 in Human Reproduction
Verified
Journal Article
Open access
PDF file
MCM Carrera
M Carrera
JDJ.A Dominguez
J.A Dominguez
FMF Pérez Milán
F Pérez Milán
MCMarina Caballero-Bellón
Marina Caballero-Bellón
LAL Alonso
L Alonso
TCT Carugno
T Carugno
Study question: Are recombinant FSH biosimilars approved by the European Medicines Agency (EMA) comparable in efficacy and safety to the originator follitropin alfa? Summary answer: Pooled analysis from studies comparing EMA-approved biosimilars with the reference product did not detect differences in efficacy or safety between these two gonadotropins. What is known already: A biosimilar is, according to EMA, a biological medicine highly similar to another already approved (‘reference’), and are approved according to the same standards of quality, safety and efficacy. Their development and approval opens a window of opportunity to make IVF treatments more affordable for the general population. Two previous meta-analysis of phase III non-inferiority randomized controlled trials (RCT) including non EMA-approved rFSH biosimilars (Chua et al., 2021 and Budani et a., 2021) have suggested that pregnancy and live births are lower with biosimilars compared to follitropin alfa. Study design, size, duration: Systematic review with meta-analysis following PRISMA guidelines. Participants/materials, setting, methods: Databases searched from inception to november 2021 were: PubMed-MEDLINE, WOS, The Cochrane Library, ClinicalTrials.gov, EudraCT and Google Scholar using these keywords: ‘biosimilars’, ‘follitropin alfa’, `originator’ and ‘ovarian stimulation’. RCTs and non-randomized comparative studies were included. Risk of bias was assessed with ROB-2 tool and Newcastle-Ottawa Scale studies. Pooled Odds Ratios (OR) and mean differences (MD) when applicable, with a 95% confidence interval (CI), were calculated. PROSPERO protocol registration has been requested. Main results and the role of chance: After the systematic search,five studies were included in the meta-analysis: two phase-III RCT (Strawitzki, 2016 and Rettenbacher, 2015) and three non-randomized comparative studies, one of them prospective (Kaplan 2021) and the other two retrospective (Sprem Goldstajn, 2021 and Van den Haute, 2021) involving 2173 IVF cycles. Risk of bias was low for the two RCT and moderate for the observational studies. The OR of clinical pregnancy was 0.89 (95% CI = 0.74,1.07; I2=0%) and the OR of live birth was 0.86 (95% CI = 0.71,1.04; I2=0%). No differences were observed in the cumulative birth rate either (OR = 0.86; 95% CI = 0.68, 1.09; I2 0%). The total number of oocytes retrieved was similar (MD = 0.25; 95%CI,-0.93, 1.43; I2 79%); as it was the total dose of gonadotropins employed (MD=-19.56; 95% CI, -57.88, 18.76; I2 0%) and the length of the stimulation (MD = 0.12; 95% CI,-0.23, 0.47; I2 80%). The risk of Ovarian Hyperstimulation Syndrome was similar in both cases (OR = 1.36; 95% CI, 0.63, 2.91; I2 21%). Limitations, reasons for caution: Main limitations of this meta-analysis include the fact that three of the five included studies are not randomized studies and two of them are retrospective, which can bias the results. Wider implications of the findings: This is the first meta-analysis including only results from studies with biosimilars EMA-approved. The results show that there are no differences between the biosimilars and the reference in terms of efficacy or safety. Larger RCTs including patients with different patterns of ovarian response are needed to confirm these findings. Trial registration number: Not applicable

28 April 2025
Verified
Preprint
Open access
VLVicente Santa-Maria Lopez
Vicente Santa-Maria Lopez
AFAnna Felip-Badia
Anna Felip-Badia
MCMarina Caballero-Bellón
Marina Caballero-Bellón
NSNazaret Sánchez-Sierra
Nazaret Sánchez-Sierra
ACAlicia Castañeda
Alicia Castañeda
Jaume MoraJaume Mora
Jaume Mora
Introduction : Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available. Novel therapeutic approaches, such as intraventricular radio-immunotherapy with 131 I-Omburtamab (Omb), have been developed. In this study, we report a retrospective, single tertiary center analysis of a 23-year cohort of NB patients with CNS metastases, highlighting current treatment strategies. Patients and Methods : Retrospective data analysis of all NB patients with CNS metastases treated at Hospital Sant Joan de Déu, Barcelona, from January 2000 to January 2023. Patient characteristics at diagnosis, first-line treatment, relapse patterns, and CNS metastasis management were analyzed in search of risk variables and survival outcomes. Results : CNS metastases at relapse were identified in 39/185 (21.1%) patients. Median age at diagnosis was 2.7 years, and 24/39 male. Stage 4 NB with multisite metastases accounted for most cases (92.2%). CNS events occurred predominantly at first relapse (29/39, 74.4%) and with neurological symptoms (23/38, 60.5%). MCYN amplification and concomitant extra-CNS metastases at CNS relapse were associated with poorer overall survival (OS) ( p =0.018 and p =0.0059, respectively). Neurological symptoms upon relapse significantly increased the risk for subsequent CNS events ( p =0.028). Curative-intent of treatment was attempted in 34/39 (87.2%) patients. After adjusting for immortal time bias, RT plus Omb significantly improved OS ( p <0.0001). Conclusions : In our experience, MYCN amplification and concomitant extra-CNS metastases at CNS relapse significantly decrease OS. Multimodal treatment including Omburtamab radioimmunotherapy significantly improves survival outcomes.